Table 2.
Comparative analysis of the clinicopathological findings between wild-type and mutated KRAS groups
| Variables |
KRAS
Wild-type n = 34 (68.0%) |
KRAS
Mutated n = 16 (32.0%) |
Univariate P* |
|---|---|---|---|
| Clinical factors | |||
| Sex | |||
| Male/female | 19/15 | 10/6 | 0.763 |
| Age (years) | 69 (32 − 81) | 69 (47 − 84) | 0.303 |
| CEA (ng/mL) | 2.8 (0.4 − 133.1) | 4.0 (1.0 − 116.6) | 0.163 |
| CA19-9 (IU/mL) | 65.0 (0.8 − 3055.0) | 38.7 (0.7 − 766.0) | 0.593 |
| Tumor size (cm) | |||
| Radiographical | 4.0 (1.0 − 13.0) | 3.0 (1.0 − 14.0) | 0.493 |
| Treatment factors | |||
| R0 resection, n (%) | 33 (97.1) | 15 (93.8) | 0.542 |
| Minor hepatectomy, n (%) | 4 (11.8) | 2 (12.5) | 1.000 |
| Morbidity | |||
| C-D class III/IV, n (%) | 9 (26.5) | 3 (18.8) | 0.728 |
| Preoperative chemotherapy | |||
| Present, n (%) | 0 | 0 | 0 |
| Adjuvant chemotherapy | |||
| Present, n (%) | 22 (64.7) | 8 (50.0) | 0.366 |
| Pathological factors | |||
| Tumor differentiation | |||
| Well/moderate, n (%) | 31 (91.2) | 12 (75.0) | 0.190 |
| Poor, n (%) | 3 (8.8) | 4 (25.0) | |
| GLUT-1 expression | 1.0 (0.0 − 4.0) | 4.0 (2.0 − 4.0) | < 0.001 |
| Vascular invasion | |||
| Present, n (%) | 22 (64.7) | 12 (75.0) | 0.533 |
| Bile duct invasion | |||
| Present, n (%) | 16 (47.1) | 8 (50.0) | 1.000 |
| Lymph node metastasis | |||
| Present, n (%) | 10 (29.4) | 5 (31.3) | 1.000 |
| Tumor number | |||
| Multiple, n (%) | 6 (17.6) | 9 (56.3) | 0.008 |
| Tumor size (cm) | |||
| Pathological | 3.6 (1.0 − 13.0) | 3.4 (1.0 − 14.0) | 0.532 |
| AJCC stage | |||
| IV, n (%) | 16 (47.1) | 9 (56.3) | 0.762 |
AJCC American joint committee on cancer/international union against cancer classification, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, GLUT-1 glucose transporter-1, R0 resection no macroscopic and microscopic tumor remaining, C-D Clavien-Dindo classification system
*Statistically significant differences (P < 0.05) are shown in italic